Cargando…
Molecular imaging biomarkers for cell-based immunotherapies
While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477274/ https://www.ncbi.nlm.nih.gov/pubmed/28629457 http://dx.doi.org/10.1186/s12967-017-1240-6 |
_version_ | 1783244757852487680 |
---|---|
author | Haris, Mohammad Bagga, Puneet Hariharan, Hari McGettigan-Croce, Bevin Johnson, Laura A. Reddy, Ravinder |
author_facet | Haris, Mohammad Bagga, Puneet Hariharan, Hari McGettigan-Croce, Bevin Johnson, Laura A. Reddy, Ravinder |
author_sort | Haris, Mohammad |
collection | PubMed |
description | While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients’ prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells. |
format | Online Article Text |
id | pubmed-5477274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54772742017-06-23 Molecular imaging biomarkers for cell-based immunotherapies Haris, Mohammad Bagga, Puneet Hariharan, Hari McGettigan-Croce, Bevin Johnson, Laura A. Reddy, Ravinder J Transl Med Review While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients’ prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells. BioMed Central 2017-06-19 /pmc/articles/PMC5477274/ /pubmed/28629457 http://dx.doi.org/10.1186/s12967-017-1240-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Haris, Mohammad Bagga, Puneet Hariharan, Hari McGettigan-Croce, Bevin Johnson, Laura A. Reddy, Ravinder Molecular imaging biomarkers for cell-based immunotherapies |
title | Molecular imaging biomarkers for cell-based immunotherapies |
title_full | Molecular imaging biomarkers for cell-based immunotherapies |
title_fullStr | Molecular imaging biomarkers for cell-based immunotherapies |
title_full_unstemmed | Molecular imaging biomarkers for cell-based immunotherapies |
title_short | Molecular imaging biomarkers for cell-based immunotherapies |
title_sort | molecular imaging biomarkers for cell-based immunotherapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477274/ https://www.ncbi.nlm.nih.gov/pubmed/28629457 http://dx.doi.org/10.1186/s12967-017-1240-6 |
work_keys_str_mv | AT harismohammad molecularimagingbiomarkersforcellbasedimmunotherapies AT baggapuneet molecularimagingbiomarkersforcellbasedimmunotherapies AT hariharanhari molecularimagingbiomarkersforcellbasedimmunotherapies AT mcgettigancrocebevin molecularimagingbiomarkersforcellbasedimmunotherapies AT johnsonlauraa molecularimagingbiomarkersforcellbasedimmunotherapies AT reddyravinder molecularimagingbiomarkersforcellbasedimmunotherapies |